ISEE Stock Overview
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IVERIC bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.95 |
| 52 Week High | US$39.99 |
| 52 Week Low | US$9.39 |
| Beta | 1.1 |
| 1 Month Change | 4.91% |
| 3 Month Change | 39.10% |
| 1 Year Change | 236.28% |
| 3 Year Change | 791.74% |
| 5 Year Change | 1,413.26% |
| Change since IPO | 51.90% |
Recent News & Updates
Recent updates
Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate
Sep 06IVERIC bio Q2 2022 Earnings Preview
Jul 25Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura
Jul 05IVERIC bio: A First Take
Jun 23We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely
May 20
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Feb 01IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans
Nov 03Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)
Sep 28Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
Sep 16Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Jul 02IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses
Jun 18IVERIC bio EPS misses by $0.04
May 05We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely
Mar 12We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth
Nov 27IVERIC bio EPS misses by $0.05
Nov 02Shareholder Returns
| ISEE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 1.5% | 1.2% |
| 1Y | 236.3% | 1.1% | 24.7% |
Return vs Industry: ISEE exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: ISEE exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| ISEE volatility | |
|---|---|
| ISEE Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ISEE's share price has been volatile over the past 3 months.
Volatility Over Time: ISEE's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 163 | Glenn Sblendorio | ivericbio.com |
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases.
IVERIC bio, Inc. Fundamentals Summary
| ISEE fundamental statistics | |
|---|---|
| Market cap | US$5.51b |
| Earnings (TTM) | -US$222.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-24.7x
P/E RatioIs ISEE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISEE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$136.54m |
| Gross Profit | -US$136.54m |
| Other Expenses | US$86.37m |
| Earnings | -US$222.90m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 20.3% |
How did ISEE perform over the long term?
See historical performance and comparison